These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11741223)

  • 1. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
    Liang JF; Li YT; Connell ME; Yang VC
    AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
    Liang JF; Park YJ; Song H; Li YT; Yang VC
    J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel heparin/protamine-based pro-drug type delivery system for protease drugs.
    Liang JF; Song H; Li YT; Yang VC
    J Pharm Sci; 2000 May; 89(5):664-73. PubMed ID: 10756332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
    Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
    J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
    Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
    Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct.
    Song H; Liang JF; Yang VC
    ASAIO J; 2000; 46(6):663-8. PubMed ID: 11110262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
    Reed GL; Houng AK
    Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
    Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
    J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of "ATTEMPTS" for drug delivery.
    Naik SS; Liang JF; Park YJ; Lee WK; Yang VC
    J Control Release; 2005 Jan; 101(1-3):35-45. PubMed ID: 15588892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron and carbon monoxide attenuate Crotalus atrox venom-enhanced tissue-type plasminogen activator-initiated fibrinolysis.
    Nielsen VG; Boyer LV; Matika RW; Amos Q; Redford DT
    Blood Coagul Fibrinolysis; 2016 Jul; 27(5):511-6. PubMed ID: 26575490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro.
    Aisina R; Mukhametova L; Varfolomeyev S
    Biochim Biophys Acta; 2016 Apr; 1860(4):629-35. PubMed ID: 26723174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A faster-acting and more potent form of tissue plasminogen activator.
    Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen.
    Andrade-Gordon P; Strickland S
    Biochemistry; 1986 Jul; 25(14):4033-40. PubMed ID: 2943315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects.
    Park YJ; Liang JF; Song H; Li YT; Naik S; Yang VC
    Adv Drug Deliv Rev; 2003 Feb; 55(2):251-65. PubMed ID: 12564979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.